Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema

Plasminogen activator inhibitor‐1 (PAI‐1) is an endogenous irreversible inhibitor of tissue‐type (tPA) and urokinase (uPA) plasminogen activators. PAI‐1‐targeted fibrinolytic therapy (PAI‐1‐TFT) is designed to decrease the therapeutic dose of tPA and uPA, attenuating the risk of bleeding and other c...

Descripción completa

Detalles Bibliográficos
Autores principales: Florova, Galina, Girard, René A., Azghani, Ali O., Sarva, Krishna, Buchanan, Ann, Karandashova, Sophia, DeVera, Christian J., Morris, Danna, Chamiso, Mignote, Koenig, Kathleen, Cines, Douglas B., Idell, Steven, Komissarov, Andrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123555/
https://www.ncbi.nlm.nih.gov/pubmed/33991465
http://dx.doi.org/10.14814/phy2.14861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123555/
https://www.ncbi.nlm.nih.gov/pubmed/33991465
http://dx.doi.org/10.14814/phy2.14861

Ejemplares similares